Viral vector optimization efforts demonstrate particular promise, exemplified by AAV-mediated delivery of miniaturized dystrophin constructs achieving functional recovery in canine muscular dystrophy models with negligible adverse events (Birch et al., 2023). This evidence concerns the gene DMD and muscular dystrophy.